药康生物与益诺思签署战略协议 共同推动创新模型国际化

Core Viewpoint - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. and Shanghai Yinos Biotech Co., Ltd. have signed a strategic cooperation agreement to enhance the development and application of non-clinical safety evaluation models in the biopharmaceutical industry [2] Group 1: Collaboration Details - The collaboration aims to leverage Jicui Yaokang's expertise in mouse model development and Yinos's capabilities in non-clinical safety evaluation to standardize the application of these models in carcinogenicity research [3] - Both companies will share experimental data related to tumor incidence, latency, and histopathological characteristics to enhance the industry's recognition of the models [3] Group 2: Global Service Expansion - Jicui Yaokang will provide early drug activity screening and mechanism research services for overseas clients, while Yinos will handle subsequent pharmacokinetics and safety evaluations [4] - The partnership will establish a joint mechanism for expanding overseas clients, focusing on major pharmaceutical markets in the US, Europe, and Asia-Pacific [4] Group 3: Strategic Goals - The collaboration aims to integrate resources to validate Jicui Yaokang's mouse models within Yinos's toxicology platform, facilitating entry into the evaluation supply chain [5] - The goal is to create a benchmark cooperation model for the biopharmaceutical industry, combining Chinese model animals with Chinese safety evaluation services [5]